Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase NA 4Phase EARLY_PHASE1 3Phase 3 3Phase 1/2 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Carcinoma, Non-Small-Cell Lung 114Breast Neoplasms 79Neoplasms 74Neoplasm Metastasis 63Colorectal Neoplasms 62Prostatic Neoplasms 57Recurrence 56Pancreatic Neoplasms 55Leukemia, Myeloid, Acute 55Ovarian Neoplasms 53Multiple Myeloma 50Melanoma 39Glioblastoma 38Squamous Cell Carcinoma of Head and Neck 33Lung Neoplasms 33Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma 27Carcinoma, Renal Cell 27Lymphoma, Large B-Cell, Diffuse 26Stomach Neoplasms 25Lymphoma, B-Cell 25Carcinoma, Hepatocellular 24Advanced Solid Tumor 24Small Cell Lung Carcinoma 23Leukemia, Lymphocytic, Chronic, B-Cell 23Burkitt Lymphoma 23Brain Neoplasms 23

Interventions

Lenalidomide 2Dexamethasone 2isatuximab 1fludarabine phosphate 1fludarabine 1carfilzomib 1belantamab mafodotin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Plasma Cell × 90 days × Clear all
NCT07600151 2026-05-20

CONQUISTADOR

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Not yet recruiting
220 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06066359 2026-05-13

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
44 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Wake Forest University Health Sciences

Phase 1/2 Active not recruiting
70 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡